PROGRAM
LK-101
Personalized neoantigen
mRNA + DC vaccine
(Liver Cancer, Lung Cancer, Melanoma, Gastric Cancer)
DEVELOPMENT STAGE
United StatesClinical Phase II
ChinaClinical Phase I
Pipeline
Advancing Personalized Immunotherapy
Our pipeline translates neoantigen discovery into a growing portfolio of personalized cancer immunotherapies across multiple therapeutic modalities.
PROGRAM
LK-201
Personalized neoantigen specific T cell therapy
reinfusion product
(Solid Tumor)
DEVELOPMENT STAGE
United StatesIIT application
ChinaEarly research
PROGRAM
LK-502
Personalized neoantigen
rmRNA + LNP vaccine
(Colorectal Cancer, Adjuvant)
DEVELOPMENT STAGE
United StatesIND application
ChinaIIT application
PROGRAM
LK-503
Shared neoantigen
mRNA + LNP Vaccine
(Solid Tumor)
DEVELOPMENT STAGE
United StatesEARLY DEVELOPMENT
EARLY PORTFOLIO
LK-301 · LK-401
TCE . Bispecific antibodies
and additional technologies
DEVELOPMENT STAGE
EARLY RESEARCH
| PROGRAM | THERAPEUTIC MODALITY | EARLY RESEARCH | IIT APPLICATION | IND APPLICATION | CLINICAL PHASE I | CLINICAL PHASE II |
|---|---|---|---|---|---|---|
| LK-101 | Personalized neoantigen mRNA + DC vaccine(Liver Cancer, Lung Cancer, Melanoma, Gastric Cancer) | United States: Clinical Phase II. China: Clinical Phase I. | ||||
| LK-201 | Personalized neoantigen specific T cell therapy reinfusion product(Solid Tumor) | United States: IIT application. China: Early research. | ||||
| LK-502 | Personalized neoantigen rmRNA + LNP vaccine(Colorectal Cancer, Adjuvant) | United States: IND application. China: IIT application. | ||||
| LK-503 | Shared neoantigen mRNA + LNP Vaccine(Solid Tumor) | United States: Early development. EARLY DEVELOPMENT | ||||
| EARLY PORTFOLIOe.g, LK-301,LK-401 | TCE . Bispecific antibodies and additional technologies | : Early research. EARLY RESEARCH | ||||
